SBC Medical Group (NASDAQ:SBC – Get Free Report) released its earnings results on Friday. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.03, FiscalAI reports. The company had revenue of $58.58 million for the quarter, compared to analyst estimates of $48.90 million. SBC Medical Group had a net margin of 27.99% and a return on equity of 18.47%.
Here are the key takeaways from SBC Medical Group’s conference call:
- Q3 growth and margins accelerated: Revenue rose 35% year over year to $59 million, while operating income and Adjusted EBITDA each increased 66%; Adjusted EBITDA margin expanded 9 percentage points to 47%. Management attributed growth partly to revised service fees, equipment-related rental revenue, and the newly consolidated Waqoo segment.
- Existing clinics and the network both grew: Nine-month same-clinic revenue increased 7%, with visits up 9% and average spend per visit up 4%; the network reached 293 locations. Management expects clinic expansion to continue and cited plans to grow general-medicine services and pursue acquisitions.
- AI and longevity are longer-term growth opportunities: SBC is developing diagnostic tests and AI tools for clinic operations and personalized care, with longevity services targeted to contribute meaningfully from around 2028. Management expects AI and network scale to support further margin improvement, but did not quantify the impact or timing.
- No additional share buybacks are planned for now: Despite cash exceeding $200 million, management said it will prioritize acquisitions and new clinic openings, while continuing to focus on improving liquidity.
- Liquidity has improved, while governance changes remain in progress: October average daily trading value was about $1 million, 4.1 times July’s level, and the shareholder base grew 1.6 times. Management said it is advancing the selection of independent directors, but gave no appointment date.
SBC Medical Group Trading Up 37.6%
SBC Medical Group stock traded up $2.01 during trading on Friday, reaching $7.35. The company had a trading volume of 1,684,551 shares, compared to its average volume of 129,183. SBC Medical Group has a 12-month low of $2.78 and a 12-month high of $7.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31. The stock’s 50 day moving average price is $5.07 and its two-hundred day moving average price is $3.96. The firm has a market capitalization of $755.95 million, a price-to-earnings ratio of 15.64, a PEG ratio of 2.36 and a beta of 0.52.
Analyst Ratings Changes
A number of research firms have recently weighed in on SBC. Weiss Ratings raised shares of SBC Medical Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 9th. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of SBC Medical Group in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded shares of SBC Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 5th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.
View Our Latest Stock Analysis on SBC
SBC Medical Group News Roundup
Here’s some of the latest news about SBC:
- Positive Sentiment: Q3 revenue rose 35% year over year to $58.6 million, beating analyst expectations of $48.9 million. EPS of $0.15 also topped the $0.12 consensus estimate. Net income attributable to SBC increased 22% to $15.7 million, while operating income climbed to $26.4 million from $15.9 million. SBC Medical Q3 financial results
- Positive Sentiment: Growth was supported by higher management-services revenue, service-fee revisions and the consolidation of Waqoo. SBC also expanded its clinic network by 36 locations year over year, to 293 locations. Q3 revenue and operating update
- Neutral Sentiment: For the first nine months of 2026, revenue increased 13% year over year to $150.8 million. SBC reported $198.4 million in cash and cash equivalents at September 30. Third-quarter and nine-month results
About SBC Medical Group
SBC Medical Group Holdings provides management and support services to medical institutions, with a focus on clinics offering aesthetic medicine. Its services include support for clinic operations, marketing, staff training, procurement and customer service, allowing affiliated medical providers to focus on patient care. The group is associated with the Shonan Beauty Clinic brand and a broader network of clinics offering services such as cosmetic surgery and dermatology. Its business is centered primarily in Japan, where it supports the operations and growth of affiliated medical institutions.
Featured Stories
- Five stocks we like better than SBC Medical Group
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for SBC Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SBC Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
